Published in Law and Health Weekly, July 28th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Teva Pharmaceutical Industries Ltd..
Report 1: Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced that the U.S. District Court for the District of New Jersey has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer's Celebrex(R) (Celecoxib) Capsules, 100 mg, 200 mg, and 400 mg, holding the three patents at issue valid and enforceable. Teva plans to appeal this decision.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.